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Table 1
Pre-HCT d180
Partial Response or worse ( PR) 9 9
Very Good Partial Response or
better (VGPR)
10 0
Complete Remission (CR) 3 13
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S204test (SAS9.3) and Kruskal-Wallis test (non-parametric) were
applied to analyze the data using the Graphpad Software.
Results: The percent NK cell was highest (median: 20% of
total lymphocytes) at d14 (p: 0.0001) compared to pre and
post HCT levels and reached baseline at d 60. The percent NK
cell was higher in VGPR (n¼13) [median: 14.34% (6.29-
28.17) and 16.08 % (7.26-31.19)] compared to PR (n¼9)
[median: 8.17% (4.01- 17.3) and 7.34 %(5.79- 47.8)] respec-
tively at d 90 (p-0.019) and d 180 (p-0.045). The NK cells
expressing CD 16 was 12.2 times higher in patients after
receiving Lenalidomide (n¼18) (p-0.05) compared to pre-
lenalidomide time point.
Conclusion: After auto-HCT, NK cell recovery was reached at
60 days after HCT and was higher in VGPR compared to
PR group at later times. This observation could indicate
enhanced host NK cell immune response against MM.
Lenalidomide therapy increased the percent of NK/ CD 16+
cells that mediates ADCC immune response. Future clinical
trials will explore therapies that increase NK cell cytolytic
responses to MM cancer cells.182
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High-dose, post-transplantation Cy (PT/Cy) is a novel and
effective strategy for preventing graft-versus-host disease
(GVHD) after allogeneic blood or marrow transplantation
(alloBMT). We previously reported that regulatory T cells
(Tregs) are resistant to Cy in allogeneic reactions; activated
Tregs (CD4+CD45RA-Foxp3+hi) are relatively increased 30 and
60 days after PT/Cy in vivo and both naïve (CD4+CD45RA+-
Foxp3+) and activated Tregs are resistant to cytotoxicity
induced by activated Cy (mafosfamide) in mixed lymphocyte
reactions (MLR) in vitro. However, the mechanisms of Treg
resistance to Cy have not been understood. As resistance of
hematopoietic stem cells to Cy is dependent on expression of
the ALDH-1 family (retinaldehyde dehydrogenases), we
hypothesized that Tregs also might express ALDH as a poten-
tial mechanism of resistance to Cy. To examine ALDH
expression, we used Aldeﬂuor as an established and repro-
ducible ﬂow cytometric-based method. There was minimal
to no Aldeﬂuor-positivity in unstimulated Tregs. However,
after allogeneic stimulation in MLR, signiﬁcant subsets of
both naïve and activated Tregs were Aldeﬂuor-positive. These
ﬁndings were conﬁrmed by PCR which showed undetectable
mRNA transcript levels in unstimulated cells but signiﬁcant
upregulation of ALDH1A1 in naïve and activated Tregs at Days
3 and 7 of MLR. These ALDH+ cells persisted after mafosfa-
mide treatment but were not present in signiﬁcant amounts
in the presence of cyclosporine or rapamycin (activated Tregs,
P ¼ .027). ALDH expression correlated with expression of
the activation markers CD69 and CD25 and withproliferation. The clinical relevance of these ﬁndings was
conﬁrmed by showing Aldeﬂuor+CD4+ T cells in peripheral
blood retrieved from patients on Day 3 post-alloBMT at the
time of receiving PT/Cy. To dissect functional implications
of these ﬁndings, we explored pharmacological inhibition
of ALDH using diethylaminobenzaldehyde (DEAB). DEAB
treatment drastically reduced activation and proliferation
of CD4+CD25+ T cells in MLR (P ¼ .031 for both compari-
sons) and abolished Treg resistance to mafosfamide-induced
cytotoxicity (activated Tregs, P < .001). Therefore, resistance
of Tregs to Cy is dependent at least in part on ALDH
expression in allogeneic reactions. Given the role of ALDH
as the rate-limiting step in retinoic acid (RA) biosynthesis
and the crucial contributions of RA to both immune toler-
ance and CD4+ T cell function, pharmacologic manipulation
of this pathway may open a new avenue for modulating
alloreactivity after alloBMT.183
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Reconstitution of immune function in recipients of allo-
geneic hematopoietic cell transplantation is a prolonged
process that takes place over several years. Patients who
undergo transplantation at our facility are asked to return at
the one-year anniversary of their transplant for a compre-
hensive clinical and laboratory evaluation. We analyzed the
extent to which standard laboratory correlates of hemato-
logic and immune reconstitution at one year posttransplant
predict subsequent survival. Of 1273 patients with hemato-
logic malignancies who underwent their ﬁrst allogeneic
transplant between Jan. 1, 2001 and Dec. 31, 2010, and
survived at least one year, 875 returned for comprehensive
assessment at 12 +/- 2 months posttransplant and were
included in this retrospective study. Comparison of the
cohort of patients who returned for evaluation and those
who did not revealed no signiﬁcant differences save for
a larger proportion of patients (36.3 vs. 45.7%, p ¼ 0.002)
with high risk disease in the latter group. Patients were
classiﬁed by graft sources into 5 groups: matched related,
mismatched related, matched unrelated, mismatched unre-
lated, or unrelated cord blood (UCB). WBC, absolute
neutrophil, absolute lymphocyte, and platelet counts deter-
mined by automated cell counter were available for all
returning patients. Absolute CD4+, CD8+, CD19+, and CD56+
cell counts determined by ﬂow cytometry, and serum IgG
and IgA levels, were available for 405, 406, 389, 393, 866 and
732 patients, respectively. CD4+ lymphocytopenia at one-
year posttransplant was extremely common in all groups.
Reconstitution of CD19+ and CD56+ cells in the UCB group
was marginally better than in the other groups. However,
there were no signiﬁcant differences in the reconstitution of
CD4+ and CD8+ cells counts and serum IgG and IgA levels
according to graft sources. To determine whether any of the
common laboratory measures of immune reconstitution
observed at one year posttransplant were correlated with
subsequent survival, we conducted landmark analyses in
